Press Releases
Neumentum to Participate in Upcoming January Virtual Investor Conferences
Neumentum to Participate in Upcoming January Virtual Investor Conferences MORRISTOWN, NJ, January 5, 2021 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief...
Neumentum to Present New Data for Drug Candidate NTM-001 at the 2020 ASHP Midyear Clinical Meeting and Exhibition
Results from evaluation of novel non-opioid analgesic NTM-001, under development for post-surgical pain, support pathway to potential Phase 3 pivotal trials in 2021 MORRISTOWN, NJ, December 8, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming...
Neumentum to Participate in the Jefferies Virtual London Healthcare Conference
MORRISTOWN, NJ, November 5, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during...
Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China
Neumentum to receive $3MM upfront payment and is eligible to receive total development, regulatory and sales-based milestones of up to an additional $50MM plus royalties MORRISTOWN, NJ, October 21, 2020 – Neumentum Inc., a pharmaceutical company dedicated to...
Neumentum to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference
MORRISTOWN, NJ, September 10, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during...
Neumentum Announces Two Poster Presentations for Novel Non-opioid, Non-NSAID Analgesic Drug Candidate at PAINWeek 2020
MORRISTOWN, NJ, September 3, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present two posters with data on NTM-006, a new chemical entity (NCE) non-opioid, non-NSAID analgesic candidate that...
Neumentum Provides Corporate Update on Company’s Pipeline of Non-opioid Analgesic Programs
Neumentum Provides Corporate Update on Company’s Pipeline of Non-opioid Analgesic Programs October 2020 Type C meeting planned with the FDA for NTM-006, an oral new chemical entity with a novel mechanism of action targeting neuropathic pain Based on recent FDA...
Neumentum, Inc. Chief Executive Officer Scott Shively to Present at BIO Digital Conference
PALO ALTO, Calif., June 5, 2020 – Neumentum, Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, has posted a presentation for digital viewing for the BIO...
Neumentum Enters into Global Licensing Agreement for a Novel Class of Investigational Pain Treatments
Agreement significantly expands Neumentum’s pipeline of investigational pain therapies aimed at addressing the growing need for innovative analgesics PALO ALTO, Calif., October 10, 2019 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain...
Neumentum Presents Data on Lead Product Candidate NTM-001 at PAINWeek 2019
Neumentum's poster presentations #39, #40, #41 and #42 from PAINWeek are now available to view. - Results Support What Has the Potential To Be the First-Ever Non-Steroidal Anti-Inflammatory (NSAID) Approved for Continuous Infusion - Results Confirm Potential to...
Media Contact
Surabhi Verma
Westwicke, an ICR company
Surabhi.Verma@westwicke.com
646-677-1825
